Big Money is often the driving force behind powerful stock moves. And now medical stock Kiniksa Pharmaceuticals International (KNSA) is testing a fresh entry amid a powerful run as institutional investors load up on the stock. The Bermuda-based company focuses on acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases. Its flagship drug is Arcalyst, which treats several…
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.